June 3, 2021

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: New Drug Introduction Report pursuant to 18 V.S.A. § 4637(c) and (d)

To the Office of the Attorney General of Vermont:

On June 1, 2021, and pursuant to 18 V.S.A. § 4637(b), Glenmark Pharmaceuticals Inc., USA ("Glenmark") submitted a new drug notice for RufinamideTablets, NDC 68462-0713-08 and NDC 68462-0714-08 ("Products"). Glenmark now provides the following additional information pursuant to 18 V.S.A. § 4637(c):

1) **US and International marketing and pricing plans used at launch:** Glenmark does not make its marketing or pricing plans publicly available, and does not believe that such information is in the public domain. Accordingly, pursuant to 18 V.S.A. § 4637(d), Glenmark will not be providing this information.
2) **Estimated volume of patients who may be prescribed the drug:** Estimated number of patients is not known.
3) **Whether the FDA granted breakthrough therapy designation or priority review:** The Products did not receive priority review or breakthrough status.
4) **Date and price of acquisition:** Not applicable. Glenmark developed the Products.